Scinopharm Taiwan (TPE:1789) Beta: 0.0055 (As of Jun. 26, 2026)


TPE:1789 Scinopharm Taiwan Ltd TPE:1789
76 GF Score
Price NT$20.55
GF Value NT$27.02
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Scinopharm Taiwan Beta?

Scinopharm Taiwan TPE:1789 +1.73% 76 Beta is 0.0055 as of Jun. 26, 2026. GuruFocus rates TPE:1789 with a GF Score™ of 76/100 and a GF Value™ of NT$27.02 (Modestly Undervalued). The stock has 7 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-26), Scinopharm Taiwan's Beta is 0.0055.


Scinopharm Taiwan  (TPE:1789) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Scinopharm Taiwan Beta Related Terms


Scinopharm Taiwan Beta Historical Data

* Premium members only.

The historical data trend for Scinopharm Taiwan's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scinopharm Taiwan Beta Chart

Scinopharm Taiwan Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.36 0.23 0.09 0.14 0.00

Scinopharm Taiwan Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.00 0.00 0.00 0.00

TPE:1789 vs ZTS: Beta Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Scinopharm Taiwan's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scinopharm Taiwan Beta vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Scinopharm Taiwan's Beta distribution charts can be found below:

* The bar in red indicates where Scinopharm Taiwan's Beta falls into.


TPE:1789
76GF Score
Scinopharm Taiwan Ltd TPE:1789
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scinopharm Taiwan Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.0055 mean?
Scinopharm Taiwan (TPE:1789) has a Beta of 0.0055 as of Jun. 26, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Scinopharm Taiwan and its competitors.
Is Scinopharm Taiwan's Beta too high?
Scinopharm Taiwan's current Beta is 0.0055. Overall, Scinopharm Taiwan has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Scinopharm Taiwan's Beta compare to ZTS?
Scinopharm Taiwan's Beta of 0.0055 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Drug Manufacturers company?
A good Beta depends on the Drug Manufacturers industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Scinopharm Taiwan and its competitors. Scinopharm Taiwan's current Beta is 0.0055. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scinopharm Taiwan stock overvalued right now?
Based on GuruFocus' analysis, Scinopharm Taiwan (TPE:1789) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$27.02, compared to a current price of NT$20.55 — trading 23.9% below its estimated fair value. The current Beta is 0.0055. Scinopharm Taiwan's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Scinopharm Taiwan (TPE:1789), the current Beta is 0.0055 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Scinopharm Taiwan (TPE:1789) Overvalued in 2026?

Based on GuruFocus' analysis, Scinopharm Taiwan stock appears to be undervalued. The current stock price of NT$20.55 is trading 23.9% below its estimated GF Value™ of NT$27.02. GuruFocus considers Scinopharm Taiwan to be Modestly Undervalued.

Key valuation signals for TPE:1789:

  • Beta: 0.0055
  • GF Value™: NT$27.02 vs. price of NT$20.55 (23.9% below fair value)
  • GF Score™: 76/100 with 7 warning signs

No single metric tells the full story. See the TPE:1789 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Scinopharm Taiwan Business Description

Address Nan-Ke 8th Road, No. 1, Southern Taiwan Science Park, Shan-Hua, Tainan, TWN, 74144
Scinopharm Taiwan Ltd is mainly engaged in the manufacture of western medicines and other chemical materials, biological technology services, intellectual property rights, international trade, and the research, development, production, manufacture, and sales of Active Pharmaceutical Ingredients (API), albumin medicines, oligonucleotide medicines, peptide medicines, injections, and new small molecule drugs. The Company also provides related consulting and technical services and international trade for the above products. In addition, the Company sells chemical material reprocessed from material recycled from the Company's manufacturing process.
76GF Score

Get the complete analysis for TPE:1789

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$20.55
Price
NT$27.02
GF Value